IMW 2019: Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma
Posted: Friday, October 4, 2019
Six cycles of bortezomib, lenalidomide, and dexamethasone (VRD) induction therapy seems to lead to a higher rate of very good partial response compared with bortezomib, thalidomide, and dexamethasone (VTD) in transplant-eligible patients with newly diagnosed multiple myeloma. Deepened responses and minimal residual disease negativity support the benefit of VRD over VTD, according to Laura Rosinol, MD, PhD, of the Hospital Clinic Institut d’investigacions Biomèdiques August Pi i Sunyer, Barcelona. These findings were presented at the 2019 International Myeloma Workshop (IMW) in Boston (Abstract OAB-001).
Researchers conducted an integrated analysis of prospective phase III randomized controlled clinical trials evaluating induction therapy with VRD or VTD in transplant-eligible patients with multiple myeloma. Four studies met eligibility criteria.
The data collected showed a statistically significant and clinically relevant very good partial response rate improvement after six induction cycles with VRD compared with VTD (66.3% vs. 51.2%). The 378 patients in this analysis who were started on VRD treatment saw an increase in the very good partial response rate from 54.5% at 3 cycles to 62.7% at 4 cycles and 70.1% at 6 cycles. The 111 patients treated with VTD had an increased very good partial response rate from 35.1% at 3 cycles, to 40.5% at 4 cycles, and 55.9% at 6 cycles. Very good partial response rates after induction therapy were 80.2% and 59.5% with VRD and VTD, respectively. The minimal residual disease–negativity rates after induction therapy of 46.7% with VRD compared with 34.9% with VTD support the benefit of VRD.
Disclosure: The study authors’ disclosure information can be found at imw2019boston.org.
